H.C. Wainwright Remains a Buy on Nurix Therapeutics (NRIX)

​Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 21, Robert Burns from H.C. Wainwright reiterated a Buy rating on the stock with a $31 price target. Earlier, on January 14, BTIG reiterated a Buy rating on the stock with a $30 price target.

Analysts at BTIG noted that the bullish sentiment follows the company’s recently highlighted key 2026 objectives. Management highlighted that their bexdeg, which is a BTK degrader for relapsed chronic lymphocytic leukemia, is progressing as planned. Moreover, the phase 3 study is expected to feature a head-to-head comparison against Pirtobrutinib, the newest approved BTK inhibitor. The study will prove superiority and match emerging care standards.

In addition, Nurix Therapeutics, Inc. (NASDAQ:NRIX) is also advancing its immunology assets, with Phase 1 data for the Gilead-partnered IRAK4 degrader due in 2026. The firm highlighted that the company holds $664 million in cash, which is sufficient to fund operations into 2028.

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes innovative small molecules and antibody therapies as a novel treatment approach for inflammatory conditions, cancer, and other challenging diseases.​

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.